Detalhe da pesquisa
1.
Synthetic lethal targeting of TET2-mutant haematopoietic stem and progenitor cells by XPO1 inhibitors.
Br J Haematol
; 201(3): 489-501, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36746437
2.
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
N Engl J Med
; 381(8): 727-738, 2019 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31433920
3.
XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Nature
; 538(7623): 114-117, 2016 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27680702
4.
Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas.
Cell Mol Life Sci
; 78(4): 1837-1851, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32851475
5.
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Am J Hematol
; 96(9): 1120-1130, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34062004
6.
The SINE Compound KPT-350 Blocks Dystrophic Pathologies in DMD Zebrafish and Mice.
Mol Ther
; 28(1): 189-201, 2020 01 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31628052
7.
Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells.
Int J Mol Sci
; 22(13)2021 Jun 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34206543
8.
Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis.
Blood
; 130(9): 1132-1143, 2017 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-28630120
9.
Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.
Blood
; 129(16): 2233-2245, 2017 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28096095
10.
Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer.
Int J Mol Sci
; 20(19)2019 Sep 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31569391
11.
Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance.
Int J Mol Sci
; 21(1)2019 Dec 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31905765
12.
A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma.
Am J Hematol
; 97(2): E54-E58, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34817872
13.
Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma.
Ann Hematol
; 100(12): 3057-3060, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33009581
14.
Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.
Am J Hematol
; 91(9): 923-30, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27312795
15.
Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.
Pediatr Blood Cancer
; 63(2): 276-86, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26398108
16.
Clinical translation of nuclear export inhibitors in cancer.
Semin Cancer Biol
; 27: 74-86, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24755012
17.
Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo.
J Virol
; 88(17): 10228-43, 2014 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24965445
18.
Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.
Blood
; 122(17): 3034-44, 2013 Oct 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-23970380
19.
Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.
BMC Cancer
; 15: 910, 2015 Nov 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26573568
20.
KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models.
BMC Cancer
; 15: 941, 2015 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26620414